Stay updated on PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.

Latest updates to the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe ClinicalTrials.gov site footer now identifies the site revision as v3.8.0 instead of v3.7.2.SummaryDifference0.1%

- Check21 days agoChange DetectedA sitewide NIH banner announces that federal agencies are transitioning to use “Super Intelligence” instead of “Artificial Intelligence,” with links to updates and FAQs.SummaryDifference0.8%

- Check28 days agoChange DetectedThe ClinicalTrials.gov site footer now displays software revision v3.7.2 instead of v3.7.1.SummaryDifference0.1%

- Check35 days agoChange DetectedThe website’s footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check56 days agoChange DetectedA new revision entry v3.7.0 was added to the record history and the previous revision v3.6.6 was removed, updating the version history reflected on the page.SummaryDifference0.1%

- Check77 days agoChange DetectedA new revision entry (v3.6.6) has been added to the study's history. This updates the record from the previous version (v3.6.5).SummaryDifference0.1%

Stay in the know with updates to PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.